Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (“Sun Pharma”) has received marketing authorization (“Notice of Compliance”) from Health Canada for Winlevi® (clascoterone cream 1%). Winlevi® is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older, and the newest Health
Canada-approved formulation to target the hormonal component of acne for Canadian patients in 40 years.